Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
暂无分享，去创建一个
G. Rosner | H. Kantarjian | G. Garcia-Manero | A. Loboda | J. Hardwick | J. Cortes | C. Bueso-Ramos | W. Wierda | V. Fantin | V. Richon | J. Secrist | Hui Yang | S. Faderl | A. Ferrajoli | Cong Chen | C. Koller | J. Reilly | J. Ricker | S. Frankel | S. Randolph | Carlos Bueso-Ramos | Gail Morris | C. Bueso‐Ramos | Valeria R. Fantin | Sophia S. Randolph | James S. Hardwick | John F. Reilly | J. Paul Secrist | Stanley R. Frankel | J. Paul Secrist | C. Koller | Jorge E. Cortés | Gary Rosner | Andrey Loboda | Valeria R. Fantin | Sophia S. Randolph | James S. Hardwick | John F. Reilly | Cong Chen | Stanley R. Frankel | Gary Rosner | Andrey Loboda | Valeria R. Fantin | Sophia S. Randolph | James S. Hardwick | Cong Chen